AGENCIES,NOVEMBER 19 2021: U.S. government para drugmaker Pfizer ke $5.29 billion for 10 million treatment courses potential COVID-19 treatment ke dibo judi regulator para manishe koile toh.
Pfizer para Food and Drug Administration Tuesday din te koikena janaishe emergency use niemte etu experimental pill nimete etu toh hospitalization rate toh komti kurishe aro deaths toh manu khan majhotte coronavirus infection thakikena
Fda para hi ekta competing pill sai ase merck aro public meeting lobole etu nimete etu moina pichede.
Pfizer’s potential treatment laga daam toh komti hoi lebi Pfizer’s potential treatment te ase.us khan akhe para manishe komti hoilebi $700 per course Merck’s drug 1.7 million treatments dibole nimete.
Pfizer para Thursday din te koikena janaishe etu daam toh U.S. government para dishe etu treatment courses laga number dishe 2022 te kina toh.
Et u drugmaker para koikena janaishe tai khan submission dishe approval nimete dusra alag alag desh te aro etu te advance purchase agreement khan ase dusra government khan logote.
Tu esday din te Pfizer para ekta deal sign kurishe U.N.-backed group etu para generic drugmaekrs khan ke komti daam version bonabole niemte pill te kunba desh te nimete.merck toh eki deal thakishe pill niemte etu toh Britain para authorize kurishe etu moina akhe te.
Pfizer para etu moina olop akhe te khobor dishe tai khan laga pill para hospitalization aro deaths toh 89 percent te thakishe high risk adults khan majhotte kun khan covid 19 laga early symptoms thaka toh.
Company par a etu pill toh manu khan te pudishe kun khan vaccinate maranai aro dukh paishe virus para age nohoile health problems khan etu te obesity para huwa toh.
Pfizer para etu drug toh adults nimete olaishe kun khan risk te ase bishi beemar hobole niemrtedusra drugs nishena etu beemar te elach luwa toh.
Hoilebi sob FDA-authorized COVID-19 treatments toh iv nohoile injection lagi ase health professional para diya toh hospital nohoile toh clinic te.
Pfizer toh akhe para komti hoilebi $24 billion in global revenue te kamaishe etia tak etu sal comirniat y te etu covid 19 vaccine kuntu toh joldi hi drugmaker’s top-selling product hoishe.
New York-based Pfizer Inc. laga shares toh komti hoilebi 25 cents to $51.12 early trading te uthise.
